Status:
UNKNOWN
Complete Pathologic Response Rectal Cancers
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborating Sponsors:
European Society of Surgical Oncology
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Background. About 20% of rectal cancers who underwent neoadjuvant treatment (neoCHT-RT) achieve a pathological complete response in the surgical specimen(ypT0); however, about 10% of ypT0 present meta...
Detailed Description
Prospectus. The COmplete pathologic ReSponse rectal Cancers EYSAC.1 Study (CORSiCA) proposed by Dr Lorenzon will be conducted at the Fondazione Policlinico Universitario Agostino Gemelli in Rome in pa...
Eligibility Criteria
Inclusion
- Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection
- Final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
Exclusion
- Patients treated with chemotherapy-only protocols
- Stage IV
- Patients presenting peri-operative mortality (\< 30 days from the surgical procedure)
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2018
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03351959
Start Date
January 1 2018
End Date
September 1 2018
Last Update
May 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Unversitario Agostino Gemelli
Roma, Italy, 00168